初治淋巴瘤患者血浆中VEGF-C、VEGF-D、VEGFR-2及VEGFR-3的表达水平及临床意义

本研究检测初治淋巴瘤患者血浆中血管生成相关因子VEGF-C、VEGF-D、VEGFR-2、VEGFR-3的表达水平,探讨其与淋巴瘤临床特点及预后的相关性,寻找指导淋巴瘤抗血管靶向治疗及判断预后的有价值的指标和因素。应用酶联免疫吸附测定的方法检测86例初治淋巴瘤患者血浆中VEGF-C、VEGF-D、VEGFR-2、VEGFR-3的表达水平。结果表明,多因素分析结果显示,VEGF-C在非霍奇金淋巴瘤患者中呈低表达水平,而在霍奇金淋巴瘤患者中表达水平较高;VEGFR-2在年龄>60岁淋巴瘤患者中表达较高;VEGF-D在IPI>2分的患者组中表达较低。单因素分析显示,VEGF-D在IPI>2分患者组中呈低水平表达;VEGF-D、VEGF-C在无B症状组高水平表达。因子间的关联性分析表明,VEGF-D与VEGFR-2、VEGFR-3的表达水平呈正相关。结论:VEGF-C、VEGF-D、VEGFR-2、VEGFR-3在淋巴瘤的发病中具有重要作用,可作为细化指导淋巴瘤抗血管靶向治疗、了解病情、判断预后的指标。

Plasma levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in patients with newly diagnosed lymphomas

The objective of this study was to detect the expression levels of VEGF-C,VEGF-D,VEGFR-2 and VEGFR-3 in plasma of newly diagnosed lymphoma patients,and analyze their possible relationships with clinicopathological characteristics and prognosis.The expression levels of VEGF-C,VEGF-D,VEGFR-2 and VEGFR-3 in plasma from 86 newly diagnosed lymphoma patients were detected by enzyme-linked immunosorbent assay（ELISA）.As a results,the multivariate analysis showed that VEGF-C level in non-Hodgkin′s lymphoma patients was low,but high in Hodgkin′s lymphoma patients;VEGFR-2 level was higher in patients 60 years,while VEGF-D level was lower in patients with IPI 2.The univariate analysis showed that VEGF-D level was lower in patients with IPI2,while VEGF-D and VEGF-C levels were higher in patients without B symptoms.Relationship analysis between these factors indicated that the relation of VEGF-D expression level with VEGFR-2 and VEGFR-3 was positive.It is concluded that VEGF-C,VEGF-D,VEGFR-2 and VEGFR-3 play important roles in the pathogenesis of lymphoma,and may be used as indicators of prognosis evaluation or even guide for the antiangiogenesis treatment of lymphoma.